Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment

NCT03687333 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Glycogen Storage Disease Type II

Interventions

DRUG: ALGLUCOSIDASE ALFA (MYOZYME)

Sponsor

Genzyme, a Sanofi Company